Ruthenium pyridyl thiocyanate complex increased the production of pro-inflammatory TNFα and IL1β cytokines by the LPS stimulated mammalian macrophages in vitro
- 51 Downloads
Every cell in our body depends on the electron transport processes in order to generate energy and function properly. Being able to regulate the metabolic activity of a cell would enable us altering its function and eventually lead us to a desired biological outcome at the cellular level and more desirably at a systemic level. Immunomodulatory or immunostimulatory molecules have been focus of the recent studies in order to regulate or boost the activities of the immune system cells and suppress or eliminate the disease conditions such as cancer, autoimmune reactions, inflammatory disorders as well as infections. In our study we used a ruthenium pyridyl thiocyanate complex, K330, to examine its effect on the activity of the innate immune system cells, macrophages in vitro. K330 was our candidate due to its application in the solar cells. Especially, due to its ability to get involved in electron transfer systems we hypothesized that it could change the activity of the immune system cells at cellular level, possibly by interfering the electron transfer reactions of the cells. Our results support our hypothesis since K330 lead to a significant increase in TNFα and IL1β cytokine production levels by LPS stimulated macrophages compared to only LPS treated control groups. Based on our in vitro results, K330 can also be utilized as an adjuvant candidate in vaccinations where the antigen itself is not sufficient to generate a proper immune response.
KeywordsTNF-α IL-6 IL-1β Inflammation Macrophage Immunomodulation Adjuvants Innate immunity
Tumor nacrosis factor-α
- RAW 264.7
Mouse macrophage cell line
Enzyme linked immunosorbent assay
I greatly appreciate the material supports of Prof. Dr. Kasım Ocakoglu from Tarsus University and Prof. Dr. Juan Anguita from CICBiogune.
Compliance with ethical standards
Conflict of interest
The author declare no competing financial or non-financial conflict of interest.
- 1.Ocakoglu K, Sogut S, Sarica H, Guloglu P, Erten-Ela S, Emen FM (2013) Influences of the electron donor groups on the properties of thiophene-pyrrole-thiophene and tert-butyl based new ruthenium II bipyridyl sensitizers for DSSCs and DFT studies. Synth Metals 174:24–32. https://doi.org/10.1016/j.synthmet.2013.04.016 CrossRefGoogle Scholar
- 20.Fagone P et al (2018) Contribution of the macrophage migration inhibitory factor superfamily of cytokines in the pathogenesis of preclinical and human multiple sclerosis: in silico and in vivo evidences. J Neuroimmunol 322:46–56. https://doi.org/10.1016/j.jneuroim.2018.06.009 CrossRefPubMedGoogle Scholar
- 23.Nicoletti F et al (1998 Jul) Blood levels of transforming growth factor-beta 1 (TGF-beta1) are elevated in both relapsing remitting and chronic progressive multiple sclerosis (MS) patients and are further augmented by treatment with interferon-beta 1b (IFN-beta1b). Clin Exp Immunol 113(1):96–99CrossRefGoogle Scholar
- 40.Dujmovic I et al (2009) The analysis of IL-1 beta and its naturally occurring inhibitors in multiple sclerosis: the elevation of IL-1 receptor antagonist and IL-1 receptor type II after steroid therapy. J Neuroimmunol 207(1–2):101–106. https://doi.org/10.1016/j.jneuroim.2008.11.004 CrossRefPubMedGoogle Scholar